Clinical Safety

The integration of high-quality trial data now offers a methodological roadmap for sponsors to satisfy regulatory safety requirements without the cost of new longitudinal clinical studies. This paradigm shift arrives at a critical juncture where the traditional randomized controlled trial, long

The engineering of autologous T-cells to express receptors for the Kappa Myeloma Antigen offers a precision-guided approach to treating the second most common blood cancer worldwide. This milestone has been realized through the commencement of the Phase 1 KOALA study, a first-in-human clinical

The historical reliance on systematic transrectal biopsies carried a non-negligible risk of sepsis and life-threatening systemic infections for many asymptomatic patients. This traditional pathway often forced a clinical confrontation with potential complications before the severity of the

Establishing a more translationally aligned approach through cross-sector collaboration is essential for identifying neurological risks before a drug reaches human clinical trials. The central nervous system remains the most daunting frontier in drug development due to its sheer structural

The proliferation of over one thousand high-containment laboratories in the United States since 9/11 has paradoxically increased the mathematical probability of a catastrophic accident. This startling statistic serves as the foundation for Annie Jacobsen’s investigation into the burgeoning threat

Historical failures in the vitiligo pipeline, such as the cancellation of the AC##4 trial in 2016, highlight the difficulty of establishing a global site network. The recent publication of the Viti-Up Phase 3 clinical trial results in The Lancet marks a transformative moment for dermatologic